Masao Harada
Sapporo National Hospital · 97 works · 8,847 citations · h-index 26
Top works
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
- Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301
- Diagnostic Value of Endobronchial Ultrasonography With a Guide Sheath for Peripheral Pulmonary Lesions Without X-Ray Fluoroscopy
- Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
- Clinical characteristics of pleomorphic carcinoma of the lung
- Prognostic significance of the expression ofras oncogene product in non-small cell lung cancer
- Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial
- First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
- Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
- Prognostic significance of p53 andras p21 expression in nonsmall cell lung cancer
- Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
- Altered retinoblastoma protein expression in nonsmall cell lung cancer
- Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
- Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
- Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
- A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.
- Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer—CSP-HOR 13
- Nationwide Questionnaire on the Actual Status of an Interpretation System for Lung Cancer Screening by Chest Radiography